Musashi-1 (MSI1) is an RNA-binding protein that acts as a translation activator or repressor of target mRNAs. The best-characterized MSI1 target is Numb mRNA, whose encoded protein negatively regulates Notch signaling. Additional MSI1 targets include the mRNAs for the tumor suppressor protein APC that regulates Wnt signaling and the cyclindependent kinase inhibitor P21
. We hypothesized that increased expression of NUMB, P21 and APC, through inhibition of MSI1 RNA-binding activity might be an effective way to simultaneously downregulate Wnt and Notch signaling, thus blocking the growth of a broad range of cancer cells. We used a fluorescence polarization assay to screen for small molecules that disrupt the binding of MSI1 to its consensus RNA binding site. One of the top hits was (À)-gossypol (Ki ¼ 476 AE 273 nM), a natural product from cottonseed, known to have potent anti-tumor activity and which has recently completed Phase IIb clinical trials for prostate cancer. Surface plasmon resonance and nuclear magnetic resonance studies demonstrate a direct interaction of (À)-gossypol with the RNA binding pocket of MSI1. We further showed that (À)-gossypol reduces Notch/Wnt signaling in several colon cancer cell lines having high levels of MSI1, with reduced SURVIVIN expression and
Introduction
Musashi-1 (MSI1) is an evolutionarily conserved protein best known for its role in neural development in invertebrates. Msi1 was first identified in Drosophila where it helps establish different levels of Notch signaling in the daughters of a sensory organ progenitor (SOP) cell (Nakamura et al., 1994) . Subsequent studies indicate a similar role for Msi1 in the asymmetric divisions of other precursor cells, including Drosophila male germline stem cells (Kaneko et al., 2000; Okano et al., 2005; Potten et al., 2003; Siddall et al., 2006) . Homologs of Drosophila Msi1 have been identified in other species including mouse, Xenopus and humans (Charlesworth et al., 2006; Kaneko et al., 2000; Potten et al., 2003; Sakakibara et al., 1996; Sugiyama-Nakagiri et al., 2006; Toda et al., 2001) , where the protein is also expressed in stem cells and/or other precursor cell populations. Other MSI1 functions have been identified including a role in microRNA biogenesis (Kawahara et al., 2011) . MSI1 is also overexpressed in a variety of human cancers, including glioblastoma, breast, and colon cancers (Fan et al., 2010; Ma et al., 2008; Potten et al., 2003; Seigel et al., 2007; Sureban et al., 2008; Toda et al., 2001; Wang et al., 2010; Ye et al., 2008; Yokota et al., 2004) , with the highest levels occurring in late stage cancers (Fan et al., 2010; Li et al., 2011; Sureban et al., 2008; Wang et al., 2010) . Taken together, these data indicate that MSI1 is a cell fate determinant that drives cells toward the less differentiated (more proliferative) fate through maintenance of high levels of Notch and/or Wnt signaling (further discussed below). The loss of MSI1 expression from stem cells or other precursor cell populations results in the loss of such cells and a corresponding expansion of differentiated cell populations, while the over-expression of MSI1 leads to the expansion of undifferentiated and a decrease in differentiated cell populations (Okano et al., 2005; Siddall et al., 2006) . Several observations suggest that MSI1 upregulates Notch and Wnt signaling by repressing the translation of Numb Takahashi et al., 2013) and APC (adenomatous polyposis coli) (Spears and Neufeld, 2011) , which act as negative regulators of Notch and Wnt signaling, respectively (Moon and Miller, 1997; Pece et al., 2004) . MSI1 also represses translation of P21 WAFÀ1 (Battelli et al., 2006) , a negative regulator of cell cycle progression. MSI1 contains a well-conserved RNA binding domain (RBD) and exhibits sequence-specific RNA binding activity in vitro (Battelli et al., 2006; Imai et al., 2001; Spears and Neufeld, 2011) . Numb, APC and P21 mRNAs each contain at least one copy of the MSI1 consensus RNA binding sequence (MCS) (Battelli et al., 2006; Imai et al., 2001; Spears and Neufeld, 2011) , and the direct binding of MSI1 to these sites has been established for both Numb and P21 WAFÀ1 (Battelli et al., 2006; Imai et al., 2001 ). In the case of APC and Numb, deletion of the sites from the 3 0 -UTRs resulted in increased luciferase expression in luciferase reporter assays Spears and Neufeld, 2011) . Post-transcriptional regulation mediated by MSI1 can also be positive. Translational activation activities of MSI1 have been reported in pre-cerebellar neurons during midline crossing (Kuwako et al., 2010) and during Xenopus oocyte maturation (Charlesworth et al., 2006) .
Our focus is on the function of MSI1 in tumorigenesis and on the development of small molecule inhibitors of MSI1 as a possible novel therapeutic approach. The identification of compounds that specifically interfere with proteineprotein interactions is recognized as a challenging task, there is an even more severe lack of compounds that directly disrupt proteineRNA interactions. While previous studies have identified small molecule inhibitors of MSI family proteins, none of these studies measured in vivo anti-cancer activities (Clingman et al., 2014; Minuesa et al., 2014) . In this work, we use a fluorescence polarization (FP) competition assay to identify (À)-gossypol, a natural product from cottonseed, as a potent inhibitor of MSI1-RNA binding. We further show using surface plasmon resonance (SPR) and nuclear magnetic resonance (NMR) assays that (À)-gossypol binds MSI1 directly, and inhibits Notch and Wnt signaling in a variety of colon cancer cell lines. (À)-Gossypol has completed Phase IIb multicenter clinical trials for treating prostate cancer (e.g., NCT00286806, NCT00286793, NCT00666666) and a variety of other cancers (e.g., NCT00275431, NCT00397293). These clinical trials stemmed from previous work including ours, which showed that (À)-gossypol induces autophagy and apoptosis in prostate and other cancer cell lines through inhibition of the Bcl-2 family of anti-apoptotic proteins (Keshmiri-Neghab and Goliaei, 2014; Lian et al., 2011; Meng et al., 2008; Mohammad et al., 2005; Paoluzzi et al., 2008; Zhang et al., 2003 Zhang et al., , 2010 . Our in vitro fluorescent polarization binding assays indicate that (À)-gossypol has a similar or higher affinity for MSI1 (Ki ¼ 476 AE 273 nM) than that of the Bcl-2 family member, BCL-xL (Ki ¼ w0.48 mM) (data not shown and US patent 8163805 B2 (Wang et al., 2012) ). (À)-Gossypol has a lower affinity to BCL-2 than BCL-xL (IC50 10 mM vs 0.4 mM) in the same experiment condition (Wang et al., 2012; Zhang et al., 2003) . This suggests that (À)-gossypol might have value in treating colon and other cancers associated with high levels of MSI1 expression.
Materials and methods

2.1.
Cell culture and reagents (Chan et al., 2002) . All cells were maintained in DMEM (Mediatech, Manassas, VA) supplemented with 10% fetal bovine serum (FBS) (SigmaeAldrich, St. Louis, MO), 1% Glutamine (Mediatech), 1% antibiotics (Mediatech). (À)-Gossypol was isolated from racemic gossypol as we previously described (Lian et al., 2011; Meng et al., 2008) .
(3, 4-Dimethoxyphenyl) methanimine gossypol (MP-Gr) was synthesized from gossypol (Supplementary Methods). The (À)-Gossypol and MP-Gr powder were dissolved in DMSO at 20 mM as stock solutions. Cell growth, western blot analysis, Caspase-3 activation assay, RT-PCR and quantitative realtime PCR were carried out according to our previous publications (Li et al., , 2013 Lian et al., 2011; Meng et al., 2008; Wu et al., 2010 
MTT-based cytotoxicity assay
Cell viability was determined by the MTT-based assay using Cell Proliferation Reagent WST-8 (GenScript, Piscataway, NJ). Cells (4000e5000 cells/well, except WI-38 was 10,000 cells/ well) were plated in 96-well culture plates, and serially diluted testing compounds were added to the cells in triplicates. Four to six days later, when DMSO control wells reach confluences, WST-8 was added to each well and incubated for 2 h at 37 C.
Absorbance was measured with Synergy H4 plate reader (Biotek, Winooski, VT) at 450 nm with correction at 650 nm. The results are expressed as the percentage of absorbance of treated wells versus that of DMSO control. IC50, the drug concentration causing 50% growth inhibition, was calculated via sigmoid dose response curve fitting using GraphPad Prism 5.0 (GraphPad, Winooski, VT).
Colony formation assay
For colony formation assay, cells were seeded in 6-well plate in triplicate (400 cells/well) and treated with (À)-gossypol, MP-Gr at different dose or DMSO control (concentration 0 in both (À)-gossypol and MP-Gr treated samples). 0.5 ml of FBS was added to each well at day 5. After 10 days of incubation, plates were gently rinsed with PBS and stained with 0.1% of crystal violet (in PBS). Colonies with over than 50 cells were counted manually. Survival fraction was calculated by dividing the number of colonies in the treatment group by that of the DMSO control.
Protein expression and purification
pGEX4T-1-MSI1 and pET21a-GB1-RBD1 plasmids encoding full length MSI1 and the RNA binding domain 1 (RBD1, residues 20e107) of MSI1 were constructed with Mus musculus cDNAs under Tac and T7 promoter, respectively. The amino acid sequence of RBD1 is identical in Homo sapiens and Mus musculus. GST-MSI1 and GB1-RBD1 proteins were expressed in E. coli and purified as previously described (Estrada et al., 2009; Harper and Speicher, 2011) with modifications for GB1-RBD1 protein production (Supplementary Methods).
Fluorescence polarization competition assay
The oligonucleotide sequence for MSI1 RNA binding studies was 5 0 -UAGGUAGUAGUUUUA-3 0 , corresponding to 2781e2795 of the published Numb mRNA sequence (NM_001272055.1) and was previously shown to bind MSI1 . A 16-nt fully degenerative control RNA was used as a negative control. Control RNA is a mixture of 16-nt oligos with random sequences. The 3ʹ-fluoresceinlabeled Numb and control RNAs were purchased from Dharmacon (Thermo Scientific, Lafayette, CO) and deprotected as recommended by the manufacturer. Unlabeled versions of the Numb and control RNAs, used in RNA competition assays, were purchased from IDT (Coralville, IA). FP assays were carried out according to previous publications with our modification (Aviv et al., 2003; Pagano et al., 2011) . Briefly, before binding analysis, RNAs were heated to 95 C for 5 min and immediately cooled on ice for 5 min. For the determination of equilibrium dissociation constants (Kd), purified proteins were serially diluted in binding buffer containing 150 mM NaCl, 20 mM HEPES, pH 7.4, 1 mM DTT, 0.05% pluronic F-68, and aliquoted to 96-well assay plates (Corning 3915) (Corning, Corning, NY). For binding reactions, 2 nM of fluorescein-labeled RNA was added to each well and incubated at room temperature for 30 min. Anisotropy measurements were taken at room temperature using a BioTek Synergy H4 plate reader (Biotek, Winooski, VT) following the protocol recommended by the manufacture. The Kd was estimated by nonlinear regression to a one-site binding model using GraphPad Prism 5.0 (GraphPad, San Diego, CA). For RNA competition assays, increasing concentrations of unlabeled Numb or control RNAs were added to pre-formed Numb RNA-protein complexes. For the drug screening/ competition assay, different testing compounds with single (10 mM) or multiple concentrations (6 doses ranging from 2 nM to 200 mM) were added to each well prior to the addition of the Numb RNA-protein complexes. After 2 h of incubation at room temperature, anisotropy measurements were taken. IC50, the drug concentration causing 50% inhibition, was calculated via sigmoid dose response curve fitting using Prism 5.0. Ki value was calculated using free online software (http://sw16.im.med.umich.edu/software/calc_ki/). The percent of inhibition was normalized such that the FP value of the protein-RNA complex with DMSO was defined as 0% inhibition, while the FP value obtained with the same concentration of the free RNA alone was defined as 100% inhibition.
Surface plasmon resonance (SPR)
The SPR experiments were performed using a BIACORE 3000 (GE Healthcare, Little Chalfont, UK) equipped with a CM5 sensor chip. GB1-RBD1 protein was immobilized using amine-coupling chemistry (Supplementary Methods). For drug studies, test compounds were dissolved in 20 mM HEPES, 1 mM DTT, 100 mM NaCl, 0.05% Pluronic F-68, 5% DMSO, and pH 7.4, and passed over the flow cells in duplicate at concentrations ranging from 2.5 mM to 50 mM at a rate of 30 ml/min at 20 C. Reaction complexes were allowed to associate and dissociate for 160 seconds each. The surfaces were regenerated with a 10-second injection of 10 mM glycine (pH 3.0, 0.2% SDS). The curves were calculated from the experimentally observed curves by successive subtractions of signals obtained for the reference surface and signals for the running buffer injected under the same conditions as testing compound.
Nuclear magnetic resonance (NMR)
For NMR analyses, 15 N-labeled GB1-RBD1 protein was produced as previously described (Estrada et al., 2009 ). The MSI1 target RNA sequence used for NMR studies was purchased from IDT. This RNA oligomer (GUAGU) was previously discovered to be the minimal sequence required for MSI1 recognition and binding (Ohyama et al., 2012) . The 15 Nlabeled GB1-RBD1 was prepared at the concentration of 200 mM in NMR buffer (50 mM sodium phosphate pH 7.0, 100 mM NaCl, 10 mM b-mercaptoethanol and 10% D 2 O). Labeled GB1-RBD1 was titrated with increasing amounts of (À)-gossypol to obtain molar protein:drug ratios of 1:0, 1:0.5, 1:1, and 1:2. 2D-1 H-15 N HSQC spectra were recorded for each titration at 298 K on a Bruker Avance 800 MHz NMR instrument, equipped with a triple resonance ( 1 H/ 13 C/ 15 N) cryoprobe. NMR backbone assignments for MSI1-RBD1 were obtained from the BMRB (entry 11450). Data was processed using NMRPipe (Frank Delaglio et al., 1995) and analyzed with NMRView (Johnson, 2004) .
Computational modeling
The model of (À)-gossypol bound to MSI1, was built from the three-dimensional structure of RBD1 in complex with RNA (PDB: 2RS2) (Ohyama et al., 2012) . We first built the structure of gossypol and its hydrated aldehyde forms using Open Babel (O'Boyle et al., 2011) . We built structures of gossypol in fully hydrated form, partially hydrated form and without hydrate. The AutoDock tools from the MGL software package were used to perform molecular docking studies (Morris et al., 2009 
Animal studies
In vivo experiments were carried out with 5-to 6-week-old female NCr-nu/nu nude mice purchased from the Harlan laboratory (Indianapolis, IN). Mice were inoculated subcutaneously with 0.2 ml HCT-116 cell suspension (1.5 Â 10 6 cells) using a sterile 23-gauge needle on both sides of the mice. When tumors reached 30 mm 3 , the mice were randomized into two groups with 5 mice per group. Group 1 was given 0.05% carboxymethyl cellulose (CMC) as vehicle control; Group 2 was given 10 mg/kg (À)-gossypol in 0.05% CMC. Both vehicle control and drug were administrated by oral gavage daily for 4 weeks. The tumor sizes and animal body weights were measured twice weekly and plotted according to our published methods (Lian et al., 2011) . Briefly, the tumor sizes were measured using vernier caliper, and tumor volume were calculated using formula ½(Length Â Width 2 ) (Lian et al., 2011) . One week after treatment, tumor tissues were excised and processed for western blot analysis as we previously described (Lian et al., 2011) . All animal experiments were carried out according to the protocol approved by the University of Kansas Guidelines for Use and Care of Animals.
Statistical analysis
Using Prism 5.0 software (GraphPad Prism), one-way ANOVA and t-Test were used to analyze the in vitro data, two-way ANOVA was used to analyze the in vivo data. A threshold of P < 0.05 was defined as statistically significant.
Results
FP assay identified (À)-gossypol as a potent MSI1-RNA interaction inhibitor
We used a high-throughput, FP-based assay to screen chemical libraries of small molecules for those that disrupt the binding of MSI1 to a synthetic copy of a well-characterized MSI1 binding site located in the 3 0 -UTR of Numb mRNA (5 0 -UAGGUA-GUAGUUUUA-3 0 ) . In preliminary studies, we found that both full-length MSI1 and a truncated version of the protein consisting of RBD1 only bound to Numb RNA and not to a control RNA of random sequences ( Figure 1A) , therefore demonstrating specificity of the assay. We also found that unlabeled Numb RNA could displace the labeled Numb RNA, while unlabeled control RNA did not (data not shown).
We next screened w2000 compounds from NCI (Diversity Set II, natural product set and approved oncology drugs) and inhouse libraries using full-length MSI1 and ranked them by percent of inhibition ( Figure 1B ). Several molecules, including (À)-gossypol, inhibited MSI1 binding by more than 80%. We chose (À)-gossypol for further studies since it also scored well in cell-based assays (see below), while other molecules including (þ)-gossypol did not (data not shown). Next, we carried out doseeresponse experiments using (À)-gossypol and several gossypol Schiff base analogs. As shown in Figure 1C , (À)-gossypol inhibits MSI1 RNA binding at submicromolar Ki values, while the MP-Gr, a biologically inert gossypol analog sharing the similar scaffold, did not inhibit MSI1-RNA binding ( Figure 1D ). This inhibition was confirmed using the truncated version of the MSI1 protein that only contained RBD1 ( Figure 1C ).
SPR and NMR validation of (À)-gossypol binding to MSI1
To confirm the binding of (À)-gossypol to MSI1, we carried out an SPR-based binding assay. As shown in Figure 2A , the SPR assay showed that (À)-gossypol binds to MSI1 RBD1 in a dose-dependent manner. SPR data support that (À)-gossypol interacts with MSI1 by directly binding to MSI1 protein RBD1.
To further confirm the binding of (À)-gossypol to MSI1 and to determine if this binding event affects the RNA binding residues, we employed an NMR assay. First, we reproduced the previously published spectra data for 15 N-MSI1-RBD1 bound to a synthetic RNA corresponding to the MSI1 consensus target site (GUAGU) with consistent results, as shown in Figure 2B left panel (Miyanoiri et al., 2003) . We identified known RNA binding residues W29, K93, F23 and F65 ( Figure 2B right panel) , consistent with published peak assignments of MSI1 (Ohyama et al., 2012) . Specifically, residue F65 is required for MSI1-RBD1 to bind to target RNA . In response to increasing doses of (À)-gossypol, residues W29, K93, F23 and F65 peaks exhibited line-broadening, as shown in Figure 2C , suggesting that the compound bound most closely to these residues. Thus (À)-gossypol interacts with the same binding pocket that MSI1 uses to bind target RNA. As described in the Methods section above, in silico analysis confirms a feasible binding mode for (À)-gossypol in the lower portion of the RBD1 binding pocket, with aromatic stacking interactions that mimic the cognate RNA and include three of the four shifted residues (F23, K93, F65; Figure 2C right panel). Based on the NMR line-broadening of the remote position W29, (À)-gossypol (see insert in Figure 2C ) may also bind to more than one region of the protein or induce a conformational change upon binding.
(À)-Gossypol inhibits cell proliferation, and induces apoptosis and autophagy in colon cancer cell lines
We measured MSI1 expression in human colon cancer lines and a human epithelial cell line derived from normal colon, CCD-841. As shown in Figure 3A , all of the tested colon cancer cell lines have high levels of MSI1 mRNA as compared to the control normal cell line, some of them have high levels of MSI1 protein (see Figure 3A , bottom panel Western blot). It is noteworthy that all three bands in the Western blot are MSI1 protein, confirmed by MSI1 siRNA (data not shown). We next analyzed the effects of (À)-gossypol on the growth of colon cancer cell lines with high MSI1 expression. As measured by the MTT-based cell viability assay, (À)-gossypol inhibited the viability of colon cancer cells at a lower concentration compared to the normal control CCD-841 cells ( Figure 3B ). Decrease in cancer and normal cell viability was measured following treatment with the biological inert analog of (À)-gossypol, MP-Gr, at a slightly higher concentration. From our in vitro biophysical binding data ( Figure 1C ), the binding affinity of MP-Gr (Ki > 200 mM) is more than 200 fold weaker than (À)-gossypol (Ki ¼ 0.476 AE 0.273 mM). In in vitro MTT-based cytotoxicity assay, IC50 (HCT-116) was 35.5 mM for MP-Gr versus 8.8 mM for (À)-gossypol ( Figure 3B ). Similar results were observed for other cell lines ( Figure 3B ). Consistent with these findings, at the 72 h time point, (À)-gossypol, but not the negative analog MP-Gr, inhibited cell proliferation of the three colon cancer cell lines tested in a cell growth assay ( Figure 3C ). MP-Gr showed some growth inhibition at the 96 h point. The weak activity of MP-Gr observed may be due to other non-specific targets. Similar to the growth inhibition, (À)-gossypol-treated cancer cells formed fewer colonies, as compared with the MP-Gr-treated cells (P < 0.01, n ¼ 3) ( Figure 3D, Supplementary Figure 1) . Our results indicate a w4-fold selectivity in active versus negative compounds in cancer cells with high MSI1, while they are not active in normal cells with low MSI1 (all IC50s > 40 mM) ( Figure 3B ).
Previous studies have demonstrated that gossypol induces apoptosis and/or autophagy in various cancer cell lines with high levels of Bcl-2/Bcl-xL (Lian et al., 2011; Meng et al., 2008; Zhang et al., 2003) . To determine whether (À)-gossypol induces apoptosis and autophagy in the colon cancer cell lines with high MSI1, we first measured caspase-3 and PARP cleavage levels with and without treatment of (À)-gossypol. As shown in Figure 4AeB indicating autophagy induction. To investigate the autophagic flux level, we used Bafilomycin A1, which blocks the fusion of autophagosome and lysosome, together with (À)-gossypol. Our data showed that (À)-gossypol induced efficient autophagic flux as evident by the increase of LC3II level and the decrease of P62 degradation in the presence of Bafilomycin A1 ( Figure 4D ). Taken together, these data indicate that in MSI1-overexpressing colon cancer cells, (À)-gossypol has a greater effect on cell proliferation through Wnt pathway (see below) relative to its ability to induce cell death, which is consistent with the hypothesis that (À)-gossypol is exerting its effects through MSI1 inhibition.
However, in low MSI1/high BCL-2 prostate cancer cells (Lian et al., 2011) , (À)-gossypol has a greater effect on apoptosis, presumably through its action as a BCL-2 inhibitor. . Cell lysates were prepared after 18 h and subjected to immunoblot analysis. All figures, *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 versus DMSO control.
(À)-Gossypol inhibits cell proliferation through MSI1 downstream targets
Our in vitro binding and NMR studies above indicate that (À)-gossypol inhibits MSI1-RNA interaction. This inhibition leads to increased Numb and APC expression which results in decreased Notch and Wnt signaling (Moon and Miller, 1997; Pece et al., 2004) . Accordingly, we examined the MSI1 downstream signaling pathways after (À)-gossypol treatment in HCT-116 and DLD-1 cells. Figure 5AeB show the reduced expression of activated Notch and several downstream Notch target genes, HES1, c-MYC, CYCLIN D1 (CCND1) and SURVIVIN following treatment with (À)-gossypol but not the negative analog MP-Gr. The protein level of NOTCH1 intracellular domain (NICD) is 12% less in HCT-116 cells treated with 10 mM (À)-gossypol compared to DMSO. In DLD-1 cells, when compared to the DMSO treated sample, 10 mM (À)-gossypol treatment resulted in a 26% reduction of c-MYC protein. Reduction of NICD is not obvious in DLD1cells treated with 10 mM (À)-gossypol compared to DMSO, however, there is a 30% reduction when we compared 10 mM (À)-gossypol treatment to the negative compound MP-Gr. Down-regulation of SURVIVIN was particularly striking, where levels following (À)-gossypol treatment were comparable to that treated with YM155, a known SURVIVIN inhibitor that acts downstream of Notch activation (Cheng et al., 2012) (Figure 5C ). Our data also demonstrates (À)-gossypol inhibition of Wnt/Notch signaling genes, c-MYC and CYCLIN D1. Additional evidence that (À)-gossypol inhibits Wnt signaling comes from quantitative PCR analyses, which showed reduction in AXIN2 mRNA levels in colon cancer lines following (À)-gossypol treatment ( Figure 5B) . In a functional Wnt reporter assay performed in HCT-116 cells, (À)-gossypol decreased TOP/FOP reporter signal in a dose-dependent manner ( Figure 5D ). Figure 5A , B also show (À)-gossypol dose-dependently down-regulated the MSI1 expression. Our previous study (Spears and Neufeld, 2011) and others (Rezza et al., 2010) showed that MSI1 is a Wnt target, and there is a positive feedback loop between MSI1 and Wnt (Rezza et al., 2010) . The downregulation of MSI1 is a consequence of decreased Wnt signaling. (À)-Gossypol treatment also led to the increase of NUMB and P21 protein levels ( Figure 5A ). When HCT-116 and DLD-1 cells were treated with 10 mM (À)-gossypol, NUMB protein was increased to 110% (HCT-116) and 119% (DLD-1) as compared to DMSO control. NUMB and P21 mRNAs are direct binding and translational repression targets of MSI1 (Battelli et al., 2006; Imai et al., 2001) , thus their increases in protein levels are good indications of the MSI1 inhibition. Moreover, we detected increased mRNA levels of NUMB and P21 ( Figure 5B ). As (À)-gossypol has been reported (Keshmiri-Neghab and Goliaei, 2014; Lian et al., 2011; Meng et al., 2008; Mohammad et al., 2005; Paoluzzi et al., 2008; Zhang et al., 2003 Zhang et al., , 2010 and in clinical trials (e.g., NCT00286806, NCT00286793, NCT00666666) for targeting Bcl-2 family members, we believe such increase could be non-MSI1 related. Additionally, we see some effect of MPGr on the protein and mRNA levels of several genes, consistent with the growth inhibitions observed on HCT-116 and DLD-1 cells, such effect could be due to non-specific targets. Taken together, (À)-gossypol inhibits both Wnt and Notch signaling pathways.
(À)-Gossypol inhibits HCT-116 xenograft tumor growth
We and others have shown that (À)-gossypol inhibits the growth of multiple human cancers in xenograft mouse models (Coyle et al., 1994; Ko et al., 2007; Lian et al., 2011; Meng et al., 2008; Paoluzzi et al., 2008; Wolter et al., 2006; Zhang et al., 2010) . We used a similar assay to determine if (À)-gossypol inhibits the growth of human colon cancer cells with high MSI1 in vivo. As shown in Figure 6A , daily oral administration of (À)-gossypol inhibited the growth of human colon cancer HCT-116 xenografts, as compared to the untreated control carboxymethyl cellulose (CMC) (P < 0.001, n ¼ 10). Western blotting using tumor tissue lysates show that MSI1, together with the activated NOTCH1, CYCLIN D1 and SURVIVIN protein levels were decreased in (À)-gossypol treatment group as compared to CMC control ( Figure 6B ). Based on the bands' densities, MSI1 protein was downregulated 39%, the activated NOTCH1 (NICD) 20%, and CYCLIN D1 23%, in the (À)-gossypol-treated tumor versus CMC control. As shown the lower panel of Figure 6B , SURVIVIN protein was down-regulated 55% and 43% in the two (À)-gossypol-treated tumors, as compared with CMC control. These data indicate that (À)-gossypol inhibited MSI1-Wnt/Notch signaling in HCT-116 xenograft tumors in vivo, consistent with our in vitro data. We also observed increased Caspase-3 activation in the (À)-gossypol-treated tumor sample as indicated by the increased cleaved Caspase-3 level (2.52 fold as compared to CMC control) ( Figure 6B ). These data indicate that (À)-gossypol promotes apoptosis in the treated tumor tissues, consistent with a previous report in xenograft model of head and neck squamous cell carcinoma (Wolter et al., 2006) and a prostate cancer xenograft model (Meng et al., 2008) . The animal body weight of the control and (À)-gossypol-treated mice did not differ significantly throughout the experiment ( Figure 6C ), suggesting safe oral administration of (À)-gossypol. Our data demonstrate that (À)-gossypol as a single-agent oral therapy is effective in vivo in inhibiting tumor growth of human colon cancers with high levels of MSI1.
Discussion
In this study, we report that (À)-gossypol is a potent inhibitor of MSI1-Numb RNA interaction as determined by FP-based screening. We validated direct binding of (À)-gossypol to the RBD1 of MSI1 protein using SPR and NMR, and carried out in silico docking studies to suggest a possible binding mode for the compound. Further studies showed that (À)-gossypol inhibits colon cancer cell proliferation and down-regulates both Notch and Wnt signaling pathways. Using a colon cancer xenograft model, we demonstrated that (À)-gossypol inhibits tumor growth as a single agent. MSI1 is an RNA binding protein thought to act as a cancer maintenance factor through its ability to repress NUMB, APC and P21 expression, which results in increased Notch and Wnt signaling. We used an FP assay to screen compounds for their ability to inhibit the RNA binding activity of MSI1. Our portion of the binding pocket could be due to a second, cryptic (À)-gossypol binding site or an allosteric effect of binding to the lower portion of the pocket. Additional biochemical studies and X-ray crystallography will distinguish between these two possibilities. So far, there are no reported small molecule inhibitors of the RNA-binding protein MSI1, potentially due to lacking of well-defined pocket in RNA binding domain.
Further investigation of (À)-gossypol functions showed that (À)-gossypol inhibits cell proliferation, induces apoptosis and autophagy, and represses Notch/Wnt signaling in colon cancer cell lines with MSI1 overexpression; (À)-gossypol also inhibits colon cancer xenograft tumor growth in vivo. Our previous study has shown that (À)-gossypol induces apoptosis and autophagy in prostate cancer cell lines (Lian et al., 2011 ), but does not correlate (À)-gossypol with MSI1 expression level or Wnt signaling, because Wnt signaling is not a major pathway in the initiation and progression of prostate cancers. In colon cancers, however, Wnt signaling played a major role in the tumor initiation and progression. Our working model in Figure 6D shows that in cells with MSI1 overexpression, MSI1 blocks the translation of NUMB and APC mRNA, which leads to the up-regulation of both Notch and Wnt signaling pathways. Thus MSI1 indirectly promotes proliferation/survival of the cells and inhibits cell death; (À)-gossypol binds to the RBD1 of MSI1, presumably releasing NUMB, APC and P21 mRNA from their translational repression. Increased level of NUMB and APC protein will block Notch and Wnt signaling, respectively. Increased P21 and decreased CYCLIN D1 will block cell cycle progression, which is consistent with cell cycle arrest observed in (À)-gossypol-treated HT-29 cells (Zhang et al., 2003) . Autophagy is another way to promote cell cycle arrest, as it drives cells into quiescence. We conclude that (À)-gossypol induces autophagy in colon cancer cells, and such induction puts cells into a cytostatic state with G0/G1 arrest (data not shown and ref. (Zhang et al., 2003) ); Simultaneously, (À)-gossypol blockade of the MSI1-RNA interaction leads to down regulation of Notch and Wnt signaling, thus blocking proliferation/survival ( Figure 6D) .
While (À)-gossypol shows strong binding to the newly identified target MSI1 with promising in vitro activity, it is not a specific MSI1 inhibitor as it also binds to many other targets. For example, (À)-gossypol has been shown to bind to BCL-2 family of proteins and inhibit their anti-apoptotic and/ or anti-autophagic function in various cancer cells and to inhibit tumor growth in vivo (Lian et al., 2011; Meng et al., 2008; Oliver et al., 2004; Paoluzzi et al., 2008) . Our current study identified a new target of (À)-gossypol, and validated its function in inhibiting Notch and Wnt signaling through MSI1 inhibition. (À)-Gossypol binds to MSI1 with a similar or even higher affinity than it binds to Bcl-2 family members, raising the possibility that the drug may also have utility in the treatment of cancers associated with high levels of MSI1 expression and Notch/Wnt signaling. Our future efforts will focus on further examining this novel mechanism of (À)-gossypol. Since the drug already shows promise in advanced clinical trials, such efforts may well lead to a new approach to cancer chemotherapy.
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